drugset / Trial / NCT04647890
Effects of FT011 in Systemic Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).
Timeline
- Start
- 2021-07-19
- Primary completion
- 2022-10-12
- Completion
- 2022-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASENGEPRAST | Small molecule | 200 mg | Oral |
| Subject | ASENGEPRAST | Small molecule | 400 mg | Oral |